New efficacy data reported for pivotal Study 213 shows significant, clinically meaningful improvements in agitation symptoms.
Agitation symptoms negatively impact functioning, disease progression, quality of life and care for about half of Alzheimer’s dementia patients – and are a consistent predictor of nursing home admission.5,6
REXULTI®is the first drug approved by the FDA for agitationassociated with dementia due to Alzheimer’s disease.
No safety or tolerability issues in open-label, safety lead-in phase evaluating the higher 90mg dose of efti in combination with weekly paclitaxel in the first 6 patients
Good safety profile allows for lead-in phase to be closed early and the randomized Phase II portion of study will now proceed
GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, today announced positive preclinical data in highlighting GTB-5550’s potential in prostate cancer. Martin Felices, PhD, Associate Professor of Medicine at the University of Minnesota, presented these data on Saturday, November 4th at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2023, which is being held in San Diego, California November 1-5.
The Swiss pharmaceutical giant is marketing the deal in five parts, with pricing on the longest-dated portion — a 10-year note — being discussed at 115 basis points to 120 basis points over the benchmark rate, according to a person familiar with the matter.
During a speech at the Florida Republican Party’s “Freedom Summit” in Kissimmee Saturday, Donald Trump declared that he is the only candidate who can prevent World War Three, warning that “we are closer than anyone understands” to “obliteration.”
Trump also told the crowd that “When you think of it, how important elections are, you’d have millions of people alive right now if the 2020 election was not rigged. They would be alive. Ukraine, Israel. The attack would have never been made. All of these people would be alive, the cities would be thriving.”
Trump pointed to the global chaos that is now further unfolding, noting “For four straight years, under the Trump administration, I kept America safe, I kept Israel safe, and I kept the entire world safe.”
“I kept my promise and recognized Israel’s eternal capital and opened the American embassy in Jerusalem,” Trump continued, adding “I also recognized Israeli sovereignty over the Golan Heights, and really, probably most importantly, but they did nothing with it, I withdrew from the disastrous Iran nuclear deal, but they were supposed to do something with it. And you could have because Iran did not have any money.”
“What is going on. What is going on now is shocking,” Trump urged, adding “All over the planet our enemies knew that if you tried to kill our citizens we will kill you. If you spill a drop of American blood, we will spill a gallon of your blood. That is what it was, and it was not a threat, that was just the way it was going to have to be. And we do it because we want to make sure we are not starting wars. We did not have to start wars.”
Trump further noted, “In the debate with beautiful Hillary Clinton, she said, ‘Look at him. Look at the way he talks. He is going to get us into wars. He is going to start World War III.’ And I said, ‘No, no, it is the way I talked that will keep you out of World War III.'”
He continued, “To every American is petrified that Joe Biden’s catastrophic weakness will bring our country to ruin, which he has a great chance of doing, he is close to that anyway. He’s cose to economic ruin, I make you this promise, as your president, and nobody else can say it, I will restore peace through strength, and, yes, I am the only one that will prevent World War III, because we are very close to World War III.”
Trump further warned, “this will not be a First World War or a Second World War. This will be obliteration, because the level of power, of weaponry of power you have never seen anything — you do not want to see it. When they talk about global warming, because in 250 years our ocean will be one inch higher, and they never mention the power of nuclear weapons, where one madman can do damage the likes of which nobody has ever seen before. It is just crazy. It is crazy to see it, it is crazy to talk about it.”
“But I will stop it, and it will happen very quickly. There will not be a World War III, and we are closer than anyone understands. To protect our citizens from foreign threats, I will build a state-of-the-art missile defense shield. We will build that. We will build that,” Trump vowed.
He continued, “And it will be jobs for America. It will be built in America. We developed the technology, nobody else, by the way. A lot of people said we developed the technology. The technology was developed by us, and it works. You see it. Ronald Reagan wanted to do it, but at that time they did not have the technology. The concept was good, but we have unbelievable technology. It can shoot a needle out of the air, it is incredible. Would you feel a little safer, a little more comfortable if we can do that? And it is jobs, jobs in America.”
Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), a pioneer of artificial intelligence-driven precision cardiovascular medicine tests, today announced its AI-driven molecular heart disease tests, which identify objective epigenetic and genetic biomarkers in patients suspected to be at risk or who may have coronary heart disease, has received an Innovation Technology contract from Vizient, Inc., the nation’s largest provider-driven healthcare performance improvement company.
Vizient's customer base encompasses over 60% of hospitals and 97% of academic medical centers in the United States. Through this agreement, Vizient provider customers can access Cardio Diagnostics' state-of-the-art tests at negotiated pricing, thereby increasing access to the next generation of cardiovascular disease tests.
The contract, which will be effective November 1, was awarded by Vizient based on a recommendation from its council of hospital experts, and it signifies to Vizient hospital and health system customers unique qualities that potentially bring improvement to the healthcare industry.
Cardio Diagnostics' Epi+Gen CHD and PrecisionCHD tests utilize a proprietary AI algorithm to analyze objective epigenetic and genetic biomarkers from a patient's blood sample. The company’s integrated approach, which combines artificial intelligence with DNA analysis, is at the heart of its innovation. The highly sensitive tests identify patients at risk for developing coronary heart disease or who may already have coronary heart disease through a simple blood test that can be completed remotely or in provider settings.